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Abstract: Malaria is mesoendemic in Uganda; with an entomological inoculation rate (EIR) estimated at 
562 infective bites per person year (PPY), Tororo, a rural district located in Eastern Uganda,  is one of the 
highest transmission sites.  This study leveraged participants enrolled in two NIH funded trails at the Tororo 
District Hospital in Tororo, Uganda in order to determine whether there is a difference in parasitemia levels 
and the strain dynamics of Plasmodium falciparum  between simultaneously collected venous and capillary 
blood samples over the course of 42 days of follow-up.. Parasitemia levels were examined on-site via 
microscopy of thick and thin blood smears. Capillary and venous blood samples were blotted onto filter 
paper and genotyping was conducted at Yale University in order to determine whether there are differences 
in the strain dynamics P.falciparum in capillary or venous blood. In this prospective cohort study of 196 
participants, a total of 587 simultaneously collected pairs of capillary and venous were examined. Parasite 
measurements of the capillary and venous pairs were analyzed via repeated measures of ANOVA and the 
means were proven to be different with a p-value of <0.001. These results add to the dearth of literature in 
this topic and may have implications for the protocol of clinical trials of malaria and malaria diagnosis, drug 
resistance testing, and drug efficacy testing in research settings. 
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CHAPTER I 
 
 
INTRODUCTION 
 
Section 1: Background  
The World Health Organization (WHO) Global Malaria Programme’s new 
initiative T3: Test, Treat, Track emphasizes the scale-up of universal access to diagnostic 
testing, antimalarial treatment and stronger surveillance systems in malaria endemic 
countries [1]. The basis of T3 is malaria diagnosis; accurate diagnosis is required to 
determine appropriate treatment and can improve surveillance data [2]. The WHO 
recommends that every suspected malaria case be confirmed by microscopy or a rapid 
diagnostic test (RDT) before treatment [1] and uncomplicated malaria be treated with 
Artemisinin Combination Therapy (ACT) [2]. 
The diagnosis of malaria is primarily made by demonstrating the presence of parasites in 
erythrocytes, and the gold standard remains microscopy. Blood smears are prepared by 
placing one or more drops of blood upon a glass slide for thick or thin smear preparation. 
The blood is obtained via a capillary fingerprick or a venous blood draw. While capillary 
blood is best for thick and thin smears, only a small sample can be collected each time 
[3]. Venous blood draws, which are regarded as complicated and invasive [4], are 
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performed when approximately 100uL or more of blood is needed or several blood tests 
are conducted [3]. In community settings, blood is typically obtained by capillary finger  
fingerprick, while in research settings, blood may be obtained interchangeably by 
capillary or venous sampling. or a venous blood draw. While capillary blood is best for 
thick and thin smears, only a small sample can be collected each time [3]. Venous blood 
draws, which are regarded as complicated and invasive [4], are performed when 
approximately 100uL or more of blood is needed or several blood tests are conducted [3]. 
In community settings, blood is typically obtained by capillary fingerprick, while in 
research settings, blood may be obtained interchangeably by capillary or venous 
sampling. 
Following the diagnosis of malaria, response to antimalarial therapy is judged 
by standard WHO guidelines for assessing antimalarial efficacy over multiple visits 
over 28 or more days [4, 5, 6].  During this time period, blood smears are obtained at 
specified intervals and examined both qualitatively and quantitatively for the presence 
of parasites. False positive results can lead to unnecessary treatments, contributing to 
extra financial costs, side effects, and the development of antimalarial drug resistance 
[7]. Similarly, false negative results lead to morbidity, mortality, and further 
transmission [5].  
In addition to the use of microscopy for the diagnosis of malaria and for the 
determination of antimalarial efficacy, recent interest has focused upon the
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accurate quantification of malaria parasitemia during the surveillance for artemisinin 
resistance.  Evidence from Southeast Asia suggests the emergence and spread of 
artemisinin resistance [5,6,8]. As no molecular markers exist for the detection of 
artemisinin resistance, the monitoring of resistance has relied upon the determination of  
“parasite clearance rates” following therapy [6,9]. This is typically determined through 
the quantification of parasitemia over multiple blood smears, taken up to every 6-12 
hours over the first several days of treatment. Importantly, in trial settings, blood may be 
obtained either by capillary fingerprick or venipuncture depending on the clinical setting 
and study protocol specifications. 
In addition, capillary or venous blood samples also serve as the source of DNA 
for parasite genotyping in clinical trial settings. Genotyping serves to distinguish between 
infections caused by recrudescent strains versus new infections. It is clear that malaria 
strains differ in their ability to cause disease andsevere complications based, in part, on 
their ability to cytoadhere to capillary endothelium or other peripheral locations (brain, 
placental, etc...)[10,11]. It is quite possible that due to differences in cytoadherence, 
differences in strain dynamics may be encountered between venous and capillary 
samples. 
The purpose of this study is to determine whether there is a difference in 
parasitemia levels and the presence of P.falciparum strains between simultaneously 
collected venous and capillary blood samples. 
 
 The proposed study presents several implications regarding malaria diagnosis,
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drug resistance testing, and drug efficacy testing in research settings. While capillary and 
venous blood draws are used interchangeably in malarial research, there is limited 
evidence on the consistency of parasitemia measurements of capillary and venous blood 
samples [4]. In 2011 study, analysis revealed a moderately significant difference between 
capillary and venous blood smears in one direction (P = 0.0059); P. vivax parasitemia 
levels were higher in capillary blood than in venous blood [23]. Further research is 
needed to determine the consistency of venous and capillary parasitemia measurements, 
especially in P. falciparum, the most prevalent strain in sub-Saharan Africa.  In study 
exploring P. falciparum population dynamics during the early phase of ACT in children 
with clinical malaria in Tanzania, researchers acknowledged that the definite difference 
in detected genotype pattern observed between two blood samples may have been due to 
the different blood sources: capillary and venous. To my knowledge, there are no data 
available comparing genotyping results for capillary and venous blood samples [24].    
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Section 2: Specific Aims 
1) To compare parasitemia measurements over the course of 42-day follow-up for 
the treatment of malaria from capillary and venous whole blood in children, 
pregnant women and non-pregnant adults.  
Hypothesis: Due to differences in whole blood composition and sequestration of 
parasites in capillary compartments, significant variation in parasitemia 
measurements will be seen between capillary and venous whole blood as 
measured by microscopy. 
2) To compare parasitemia measurements and parasite clearance rates over the first 
72 hours following the treatment of malaria using capillary and venous 
measurements in children, pregnant women and non-pregnant adults.  
Hypothesis: Significant differences in simultaneous venous and capillary 
measurements will be present, necessitating the consistent use of measurements 
from the same compartment over time.  
 
3) To compare genotyping results from capillary and venous whole blood in 
children, pregnant women and non-pregnant adults.  
Hypothesis: Due to differences in sequestration by parasite strains, genotyping 
results will differ in capillary and venous blood samples. 
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CHAPTER II 
 
 
METHODOLOGY  
 
Section 1: Over view  
CPCV enrolled a subset of the participants from prospective NIH-funded trials 
investigating the pharmacokinetics (PK) and pharmacodynamics (PD) of artemether-
lumefantrine (AL) in Tororo, Uganda. The CPCV study enrolled participants from 
02/27/2013 – 03/04/2014 including: HIV positive and negative pregnant women, non-
pregnant adults, and children. The three studies that CPCV participants were enrolled 
from were: an intensive PK study, a parasite clearance time study population parasite 
clearance study . In all of these studies, participants are enrolled at the time of 
presentation with uncomplicated Plasmodium falciparum malaria, and undergo venous 
and/or capillary collections to estimate antimalarial drug levels over 42 days.   
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Section 2: Study Site 
The study site is a clinic of the campus of the Tororo District Hospital (TDH) 
located in Tororo, a rural town in south-Eastern Uganda near the Kenyan border.  With 
an entomological inoculation rate (EIR) estimated at 562 infective bites per person year 
(PPY), Tororo, has one of the highest transmission sites (source). The study clinic was 
open 7 days a week from 8 a.m. to 5 p.m. with at least one physician or medical officer, 
lab technician/microscopist, and home visitor. Participants received all routine and acute 
medical care related to malaria during the 42-day follow-up at the study clinic. Those in 
need received HIV and pregnancy related care from their regular providers. However, 
study physicians were available if participants needed immediate care. 
 
Section 3: Selection and Enrollment of Participants  
Participants were referred from TDH or outside referral centers in Tororo District 
after presenting with uncomplicated P. falciparum malaria. Inclusion criteria for 
participants were: residency within 60km of the study clinic, agreement to come to clinic 
for all follow-up clinical and PK evaluations, and informed consent. Those considered 
children were between 6 months and 8 years of age and above 6kg in weight. Those that 
were considered adults were above 16 in age. Pregnancy was confirmed by appearance or 
positive pregnancy test or ultrasound. HIV status was confirmed by negative RDT test 
confirmed by Western Blot or HIV RNA.  
 Potential participants were excluded if they had a history of significant 
comorbidities including: active tuberculosis or other WHO stage 4 disease, current 
infection with non- P. falciparum mosquitos, consumption of any medication known to 
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affect CYP450 metabolism, excluding ART  or prior treatment of malaria within 14 days 
of enrollment date, hemoglobin < 7.0 g/dL, signs or evidence of uncomplicated malaria. 
Potential participants that consume any of the following medication within 3 weeks prior 
to enrollment date were also excluded: Carbamazepine, Clarithromycin, Erythromycin 
(oral), Ketoconazole, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Halofantrine. 
Grapefruit juice was avoided during the study due to its potential effects on CYP3A4. 
 
Section 4: Sample Collection Time Points  
The parent studies which CPCV participants were enrolled in followed 
participants for 42 day after they received ART.  CPCV samples were collected during a 
subset of the time point from the parent study (Figure 1). Venous or capillary samples 
were added to pre-existing time-points within the parent study. Samples were also 
collected during day of failure when the participant presented to the clinic with malaria 
symptoms and presence of parasites was verified.  
 
Section 5: Informed Consent  
 Study physician or medical officer conducted informed consent for each 
participant in the study clinic using the appropriate language for the adult or 
parent/guardians. Translaters were used when needed and the forms were available in 
the 5 most relavant languages in the study catchment areas: Jopadhola, Teso, Swahili, 
Luganda, and English. Participants has could opt out of allowing their specimen for 
future use. All forms were approved by approved by the Human Research Protection 
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Program at Yale, UCSF Committee for Human Research (UCSF CHR), Makerere 
University Faculty of Medicine - Research and Ethical Committee (FOM-REC) and the 
Uganda National Council for Science and Technology (UNCST). 
 
Section 6: Smear Preparation and Microscopy  
At each CPCV time point, a drop for a thick smear and another drop will be collected 
for a thin smear from both the capillary and the venous. The smears were stained with 2% 
Giemsa. The thick smear was used to diagnose malaria and detect parasite density, 
whereas the thin smear is used to determine the species of malaria parasite. The thin 
smear was examined only after malaria has been detected via microscopy on the thick 
smear. For malaria diagnosis, the number of asexual parasites per 200 white blood cells 
(WBCs) is counted. If there were less than 10 parasites per 200WBCs, then the count 
continued until 500 WBCs were counted. A slide was declared negative, if no asexual 
parasites were observed after counting 500 WBCs. The formulas below were used to 
calculate parasite density:  
 # of parasites per 200 WBCs X 40 = # of asexual parasites/uL 
 # of parasites per 500 WBCs X 16 =  # of asexual parasites/uL 
 
These slides will be examined were microscopy by two technicians and a third technician 
if there is a discrepancy. Slide preparation and microscopy techniques for CPCV were 
performed according to WHO guidelines [25].  
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Section 7: Data Collection 
A study physician or medical officer recorded patient data onto standardized case 
record forms (CRFs). Each patient was assigned a unique identifier. Laboratory data were 
recorded in a log and transferred to the CRFs by a study physician or medical officer. 
Study coordinators routinely conducted quality and assurance of the data. Data from the 
CRFs were transferred into a computerized data base by specialists. This data were 
archived on digital tape daily; completed tapes were transported to offsite for secure 
storage at the Kampala Data Management Center (DMC).  A subset of the data which had 
only CPCV time points were transferred from laboratory data log to a password-protected 
Excel database. To assure accuracy and security all data transfer from paper to data base 
underwent double entry. The two databases were merge to collect all the appropriate 
capillary and venous parasite density measurements for CPCV. 
 
Section 7: Data Analysis  
G*Power 3.1.6 software was used to calculate the sample size for the repeated 
measures of ANOVA test; with an alpha of 0.05, power of 0.95, estimated sample size 
was 148. These calculations were made using an effect size 0.15. The repeated measures 
ANOVA test via the SAS 9.3 software was used to analyze the data. These was  the most 
appropriate tests since the researchers were comparing the parasite density  of matched 
pairs (capillary and venous thick smears) that were matched according to an important 
characteristic: simultaneous time points.. The null hypothesis is that there is no difference 
between the means for each group (capillary versus venous). The alternative hypothesis is 
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that there is a difference between the means for each of the two groups (capillary versus 
venous). 
 
Section 8: Blood Storage and Genotyping 
Samples from capillary or venous blood were be blotted on filter paper and stored 
on collection cards according to WHO recommendations [4]. Thes samples were be 
stored in a safe place and shipped to Yale University for genotyping using a material 
transfer agreement and CDC importation permit. World Courier services were used for 
the shipment. 
Researchers attempted to analyze the capillary and venous blood samples via 
molecular methods.  DNA from blood samples obtained in Uganda were extracted via 
Qiagen DNA extraction kits for both venous and capillary samples. After extraction, the 
goal was to utlize molecular techniques to genotype strains in order to distinguish 
recrudescence (treatment failure due to drug resistance) and new infections. Most 
commonly, genotyping methods take advantage of variation in highly polymorphic genes 
of P. falciparum. Although this is achieved by PCR followed by agarose gel 
electrophoresis in many settings, we planned to use a more sensitive method, PCR 
followed by capillary electrophoresis of 3 microsatellites in the parasite to more finely 
distinguish strains from one another. Indeed, the World Health Organization (WHO) has 
recommended genotyping with capillary electrophoresis, where possible, to increase test 
sensitivity and discriminatory power [26]..  
The importance of accurate genotyping is not only in determining drug efficacy 
(true drug failure versus a new infection), but also may inform us about the pathogenesis 
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of disease. It is known that strains of P.falciparum exhibit differences in adherence 
properties in peripheral tissues. Thus, if differences exist in the strains that are detected 
in simultaneous venous and capillary samples, it may suggest that certain strains are 
more adherent in the peripheral circulation.  
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CHAPTER III 
 
 
RESULTS 
 
Section 1: Data Analysis 
Independent analysis was conducted over  
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